Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BDX vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

BDX Overall Winner 6-Pillar Tally: BDX 6 – 0 PMI Matrix Metrics: BDX 7 – 3 PMI

As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDX carries a Unified Composite Score of 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BDX vs PMI
BDX NYSE Head-to-Head Winner
Becton, Dickinson and Co.
Surgical & Medical Instruments & Apparatus
$212.68
-1.57% 1D
Market Cap $58.9B
TTM Revenue $19.5B
Forward P/E 16.0x
Beta / 30D Vol 0.16β · 26% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 24.0 Fund 48.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.7% over 20 days), RSI 63
RSI-14: 62.7 · SMA20: $207.49 · SMA50: $193.75
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (BDX 6 – 0 PMI)

Columns: Metric · BDX · PMI
1. Valuation Multiples BDX
Forward P/E 16.0x N/M
Trailing P/E 42.7x 2.9x
PEG Ratio 0.99x N/M
EV / Revenue 4.2x 3.2x
2. Growth & Scale BDX
Revenue Growth (YoY) -10.5% +38.6%
Earnings Growth (YoY) +47.6% +0.0%
TTM Revenue (USD) $19.5B $6.3M
Market Cap $58.9B $17.1M
3. Profitability & Quality BDX
Gross Margin 47.0% 18.6%
Operating Margin 15.7% -248.1%
Net Profit Margin 5.9% 0.0%
Return on Equity (ROE) 5.7% 0.0%
4. Balance Sheet & Cash Flow BDX
Cash Generation (TTM) $3.71B -$17M
Cash Flow Margin 19.1% N/A
Net Cash / Leverage $23.6B Net Debt (0.69x D/E) $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BDX
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 28.4% (9th %ile) N/A (N/A)
Put/Call OI Skew 0.41x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BDX
OpEx & R&D Intensity 31.3% of Rev ($6.09B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BDX (7) vs PMI (3)
Institutional Metric BDX PMI Criterion Row Edge
Market Capitalization
Scale
$58.9B $17.1M Larger Scale BDX
Trailing P/E Ratio
Valuation
42.7x 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
16.0x N/M Lower Multiple BDX
Revenue Growth (YoY)
Growth
-10.5% +38.6% Higher Growth PMI
Operating Margin (TTM)
Profitability
15.7% -248.1% Higher Margin BDX
Net Profit Margin
Profitability
5.9% 0.0% Higher Margin BDX
Return on Equity (ROE)
Capital Efficiency
5.7% 0.0% Higher ROE BDX
52-Week Range Position
Momentum
90% ($140–$220) 34% ($0–$18) Stronger Trend BDX
Beta / 30D Volatility
Risk Regime
0.16β · 26% Vol 54.06β · 134% Vol Lower Realized Risk BDX
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$19.5B $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.0% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.99x PEG · 4.2x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.71B ($23.6B Net Debt (0.69x D/E)) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDX +44.02 pp
BDX: +9.44% · PMI: -34.58%
3M Horizon PMI +85.49 pp
BDX: +10.77% · PMI: +96.26%
6M Horizon PMI +3395.15 pp
BDX: +44.18% · PMI: +3439.33%
1Y Horizon PMI +137.45 pp
BDX: +10.58% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BDX Revenue PMI Revenue BDX Op. Margin PMI Op. Margin Margin Leader
FY2018 $16.0B N/A 9.4% N/A BDX
FY2019 $17.3B N/A 10.2% N/A BDX
FY2020 $16.1B N/A 5.7% N/A BDX
FY2021 $19.1B N/A 11.8% N/A BDX
FY2022 $18.9B N/A 12.1% N/A BDX
FY2023 $19.4B N/A 10.9% N/A BDX
FY2024 $20.2B $0M 11.9% -312.3% BDX
FY2025 $21.8B $0M 11.8% -268.4% BDX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BDX BREAKOUT
63d in phase · OBV NEUTRAL
Current IV 28.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $212.43 · IV 25.8%

BDX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,243)

Compare $21,243 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 25.8% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $210 / $220 Bull Call Spread

Buy 1x $210C · Sell 1x $220C · 29d

Net Entry $443 Debit
T+5d @ +5% Move +$270 (+61%)
Max Risk / Buffer $443 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $200 / $190 Bull Put Spread

Sell 1x $200P · Buy 1x $190P · 29d

Net Entry $156 Credit
Max Credit / Yield +$156 (+18.5% RoM)
Max Risk / Buffer -6.6% Cushion ($844 Mgn)
5d Edge & Liquidity 78% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BDX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $58.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 31.3% of Rev ($6.09B)
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BDX vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDX carries a Unified Composite Score of 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

BDX leads the Growth & Scale pillar: BDX posts -10.5% YoY revenue growth and +47.6% YoY earnings growth on $19.5B TTM revenue (47.0% gross margin, 15.7% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BDX cumulative revenue shifted +36.7% while PMI shifted N/A. In operating R&D and SG&A reinvestment, BDX deploys 31.3% of Rev ($6.09B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

BDX screens cheaper on headline valuation multiples. BDX trades at 16.0x Forward P/E, 42.7x Trailing P/E, 0.99x PEG, and 4.2x EV/Revenue (19.1% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDX (5.7% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BDX carries 28.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.16β · 26% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.